PUMCHi004-A

General

Cell Line

hPSCreg name PUMCHi004-A
Cite as:
PUMCHi004-A (RRID:CVCL_ZX53)
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
Last update 5th October 2020
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Peking Union Medical College Hospital (PUMCH)
Owner Peking Union Medical College Hospital (PUMCH)
Derivation country China

External Databases

BioSamples SAMEA7002522
Cellosaurus CVCL_ZX53
Wikidata Q102114789

General Information

Publications
* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex male
Ethnicity Han Chinese

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Stage
Echocardiography shows hypertrophy of ventricular septum and posterior wall. Nuclear scintigaphy proves the evidence of transthyretin in heart.
Synonyms
  • Amyloidosis, hereditary, transthyretin-related
  • Corino de Andrade's disease
  • Familial transthyretin amyloidosis
  • TTR amyloidosis
  • familial amyloid polyneuropathy
  • transthyretin-related hereditary amyloidosis
show more synonyms
Genetic variants
chr18:29172901
NM_000371.3: exon2: c.112G>A
NM_000371.3: exon2: c.112G>A: p.Asp38Asn
Heterozygous
PMID:30981840; PMID:30793974
Disease associated phenotypes
  • heart failure with preserved ejection fraction
  • left ventricular hypertrophy
Family history familial history of cardiac sudden death
Is the medical history available upon request? The medical history is not available currently.
Is clinical information available? The clinical information is not available currently.

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46,XY
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA7002523

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? No
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethics Committee of Peking Union Medical College Hospital
Approval number JS-1233
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Ethics Committee of Peking Union Medical College Hospital
Approval number JS-1233
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
A preparation of autologous peripheral blood mononuclear cells (PBMCs).
Synonyms
  • Autologous Peripheral Blood Mononuclear Cell
  • Autologous PBMC
  • Autologous PBMCs
  • Autologous Peripheral Blood Mononuclear Cells
  • Therapeutic PBMCs
show more synonyms
Source cell origin
Blood circulating throughout the body.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Other

Selection criteria for clones Morphology
Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: ncEpic basal medium
Main protein source: yeast
Serum concentration: 0 %
Supplements
ncEpic 125X supplement 0.8 %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SSEA-4
Yes
TRA 1-81
Yes
NANOG
Yes
OCT4
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Cartilage Element
Ont Id: UBERON_0007844
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 6
Karyotyping method: G-Banding

Other Genotyping (Cell Line)